# US 2025/0205255 A1 · Phospholipid compositions for treating infections and inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205255 A1
- Document ID: US20250205255A1
- Status: Published application
- Kind: A1
- Application number: 18/940,361
- Filed: 2024-11-07
- Published: 2025-06-26
- Earliest claimed: 2022-01-10
- Assignees: Celestial Therapeutics, Inc.
- Applicants: Celestial Therapeutics, Inc.
- Inventors: Ajay Gupta
- Web page: https://patentgrep.com/patent/US20250205255A1

## CPC

- A61K 31/6615: Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/201: having one or two double bonds, e.g. oleic, linoleic acids
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/688: both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A pharmaceutical composition is provided which contains a phospholipid-containing composition which antagonizes toll-like receptors 1, 2, 3, 6, 7, 8 and 10. The phospholipid-containing composition consists of regioisomers and stereoisomers of palmitoyloleoylphosphatidylglycerol (POPG) consisting of at least 80% of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof, and no more than 20% of its regioisomer 1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof. The phospholipid-containing composition also has enantiomeric enrichment with at least 51% of the dextro rotatory isomer at the sn-2 position of the terminal glycerol moiety.

## Claims

### Claim at position 1

1-70. (canceled)

### Claim 71

A pharmaceutical composition, consisting of:
at least 80% of 1-palmitoyl-2-oleoyl-sn-glycerol-phospho-(1′-rac-glycerol) or a salt thereof;
no more than 20% of 1-olcoyl-2-palmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof;
no more than 1% of:
1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof;
1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof;
1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine or a salt thereof;
1-oleoyl-2-hydroxy-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof; and
1-palmitoyl-2-oleoyl-glycero-3-phosphocholine or a salt thereof;
palmitic acid; and
oleic acid.

### Claim 72 (depends on 71)

The pharmaceutical composition of claim 71, which is formulated to antagonize toll-like receptors 1, 2, 3, 6, 7, 8 and 10.

### Claim 73 (depends on 71)

The pharmaceutical composition of claim 71, wherein at least 51% of the dextro-rotatory isomer of each component is at the sn-2 position of the terminal glycerol moiety.

### Claim 74 (depends on 71)

The pharmaceutical composition of claim 71, which has an optical rotation of +8.8±1.0°.

### Claim 75 (depends on 71)

The pharmaceutical composition of claim 71, wherein the 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof is in an amount of no more than 0.25%.

### Claim 76 (depends on 71)

The pharmaceutical composition of claim 71, wherein the 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof is in an amount of no more than 0.15%.

### Claim 77 (depends on 71)

The pharmaceutical composition of claim 71, wherein the 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (P-Lyso-PC) or a salt thereof is in an amount of no more than 0.5%.

### Claim 78 (depends on 71)

The pharmaceutical composition of claim 71, wherein the 1-oleoyl-2-hydroxy-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof is in an amount of no more than 0.5%.

### Claim 79 (depends on 71)

The pharmaceutical composition of claim 71, wherein the 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine or salt thereof is in an amount of no more than 0.5%.

### Claim 80 (depends on 71)

The pharmaceutical composition of claim 71, which is free of any free fatty acids.

### Claim 81 (depends on 71)

The pharmaceutical composition of claim 71, which is free of impurities.

### Claim 82 (depends on 71)

The pharmaceutical composition of claim 71, wherein the palmitic acid is in an amount of 49.0-51.0 mol %.

### Claim 83 (depends on 71)

The pharmaceutical composition of claim 71, wherein the oleic acid is in an amount of 49.0-51.0 mol %.

### Claim 84 (depends on 71)

The pharmaceutical composition of claim 71, which is formulated as a powder for oral inhalation.
